ERBB2 and breast cancer: Furthermore, two independent studies showed that PDTO established from different types of breast cancers, including TNBC, displayed histological and genomic concordance with parental tumors as well as sensitivities to standard of care corresponding to their tumor type (chemotherapy, hormonotherapy and HER2 antibodies) [17, 18].